Distinguished in Ovarian Cancer

Karin Leunen

Belgium European Union, 
Leuven, VLG, BE 
Distinguished in Ovarian Cancer
Belgium European Union, 
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Karin Leunen practices in Leuven, Belgium. Ms. Leunen is rated as a Distinguished expert by MediFind in the treatment of Ovarian Cancer. Her top areas of expertise are Ovarian Cancer, Breast Cancer, Cervical Cancer, Endoscopy, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 65 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 27 articles in the study of Ovarian Cancer.

Gender
Female

Locations

Belgium European Union, Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies
An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies
Enrollment Status: Completed
Publish Date: May 28, 2024
Intervention Type: Drug
Study Drug: Fulvestrant
Study Phase: Phase 2

65 Total Publications

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 09, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Leunen's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile